Clinical trials Brief October 5, 2026, 10:02 AM ET

Incyte posts results of Phase 3 axatilimab trial in chronic graft-versus-host disease

Results for the Phase 3, open-label study of axatilimab in Japanese participants with recurrent or refractory active chronic graft-versus-host disease were first posted on ClinicalTrials.gov on October 5, 2026. The study enrolled 21 participants and completed primary data collection on August 6, 2025.

Primary source

ClinicalTrials.gov results record, October 5, 2026

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

Read the source: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation